CN116887834A - 多环IRAK和flt3抑制化合物以及其用途 - Google Patents

多环IRAK和flt3抑制化合物以及其用途 Download PDF

Info

Publication number
CN116887834A
CN116887834A CN202180093259.3A CN202180093259A CN116887834A CN 116887834 A CN116887834 A CN 116887834A CN 202180093259 A CN202180093259 A CN 202180093259A CN 116887834 A CN116887834 A CN 116887834A
Authority
CN
China
Prior art keywords
inhibitors
alkyl
compound
cycloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180093259.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·B·霍伊特
C·J·托马斯
D·T·斯塔奇诺夫斯基
P·J·萨特
G·J·塔瓦
C·J·菲诺奇奥
J·S·罗森鲍姆
G·格拉西亚马尔多纳多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kulom Treatment Co
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Original Assignee
Kulom Treatment Co
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kulom Treatment Co, Cincinnati Childrens Hospital Medical Center, US Department of Health and Human Services filed Critical Kulom Treatment Co
Publication of CN116887834A publication Critical patent/CN116887834A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180093259.3A 2020-12-15 2021-12-15 多环IRAK和flt3抑制化合物以及其用途 Pending CN116887834A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125654P 2020-12-15 2020-12-15
US63/125654 2020-12-15
PCT/US2021/063567 WO2022132936A1 (en) 2020-12-15 2021-12-15 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN116887834A true CN116887834A (zh) 2023-10-13

Family

ID=82058056

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180093259.3A Pending CN116887834A (zh) 2020-12-15 2021-12-15 多环IRAK和flt3抑制化合物以及其用途

Country Status (9)

Country Link
US (1) US12534469B2 (https=)
EP (1) EP4262802A4 (https=)
JP (1) JP2024500378A (https=)
CN (1) CN116887834A (https=)
AU (1) AU2021403015A1 (https=)
CA (1) CA3201690A1 (https=)
IL (1) IL303709A (https=)
MX (1) MX2023006937A (https=)
WO (1) WO2022132936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
JP2025525322A (ja) * 2022-06-15 2025-08-05 チルドレンズ ホスピタル メディカル センター 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
AU2024264188A1 (en) * 2023-04-28 2025-11-06 Kurome Therapeutics, Inc. Irak inhibitor free base, salts, and polymorphic forms thereof
WO2025029929A1 (en) * 2023-07-31 2025-02-06 Children's Hospital Medical Center Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof
WO2025137567A1 (en) * 2023-12-20 2025-06-26 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166133A1 (en) * 2008-05-13 2011-07-07 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2011123751A2 (en) * 2010-04-02 2011-10-06 Amgen Inc. Heterocyclic compounds and their uses
US20130210825A1 (en) * 2010-07-28 2013-08-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
US20180250297A1 (en) * 2015-09-09 2018-09-06 Warren C. LAU Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542261B2 (en) * 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
SG11202005237SA (en) * 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
CN110835334B (zh) * 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166133A1 (en) * 2008-05-13 2011-07-07 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2011123751A2 (en) * 2010-04-02 2011-10-06 Amgen Inc. Heterocyclic compounds and their uses
US20130210825A1 (en) * 2010-07-28 2013-08-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
US20180250297A1 (en) * 2015-09-09 2018-09-06 Warren C. LAU Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Also Published As

Publication number Publication date
JP2024500378A (ja) 2024-01-09
US20240124468A1 (en) 2024-04-18
EP4262802A1 (en) 2023-10-25
EP4262802A4 (en) 2024-11-13
WO2022132936A1 (en) 2022-06-23
AU2021403015A1 (en) 2023-08-03
US12534469B2 (en) 2026-01-27
CA3201690A1 (en) 2022-06-23
MX2023006937A (es) 2023-10-13
IL303709A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CN106255692B (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN116887834A (zh) 多环IRAK和flt3抑制化合物以及其用途
CN105308036B (zh) 用于激酶调节的化合物和方法及其适应症
CA2814419A1 (en) Cxcr4 receptor antagonists
US20200071326A1 (en) Tam kinase inhibitors
JP2023538242A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US20250154144A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
US20250368648A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN117015380A (zh) 多环IRAK和flt3抑制化合物以及其用途
WO2023150601A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途
JP2026506363A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
WO2024076614A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023250431A9 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2025137567A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101779

Country of ref document: HK